The stock of Ocugen Inc (OCGN) closed the recent trading session at $3.46, losing 1.14% from the previous trading session. During the last check, the stock of OCGN gained 28.03% to $4.43, in the after-market. The gain came after the announcement made by the company about releasing their financial results for the fourth quarter of the fiscal year 2021. OCGN also announced that the FDA has lifted the clinical hold on the company’s investigational new drug.
OCGN News
On February 18, 2022, Ocugen Inc (OCGN) made an announcement regarding the release of its financial results for the fourth quarter of the fiscal year 2022. The company said that it will host a conference call at 8:30 am E.T on February 25, 2022. OCGN will also announce the pre-market earnings on the same day.
Moreover, OCGN also announced the lifting of a clinical hold on the company’s IND by the FDA. The investigational new drug will help in evaluating the COVID-19 vaccine, BBV152, also known as COVAXIN. COVAXIN is a COVID-19 investigational vaccine that utilizes the equivalent Vero cell. Vero cell is helpful in the development of polio antibodies.
CEO Remarks
The CEO of Ocugen Inc (OCGN), Shankar Musunuri, said that they are satisfied to have the option to push forward their clinical program for COVAXIN. He further added that he trusts this clinical program will carry them closer to an alternative COVID-19 vaccine.
Moreover, Mr. Musunuri said that managing this pandemic requires more than one vaccine. They are cheered to have this option to keep fostering their vaccine.
About OCGN
Ocugen, Inc. is a clinical-stage biopharmaceutical organization that focuses on finding, developing, and commercializing quality treatments to fix visual deficiency illnesses. The company also focuses on fostering an antibody vaccine to save lives from COVID-19. OCGN is developing COVAXIN in US and Canadian markets with the help of Bharat Biotech. Ocugen have its headquarter in Malvem, Pennsylvania, United States of America (USA).
